Potential biomarker for checkpoint blockade immunotherapy and treatment strategy

被引：73

作者：

Dong, Zhong-Yi ^{[1
,2
,3
]}

Wu, Si-Pei ^{[1
,2
]}

Liao, Ri-Qiang ^{[1
,2
]}

Huang, Shu-Mei ^{[1
,2
,3
]}

Wu, Yi-Long ^{[1
,2
]}

机构：

[1] Guangdong Gen Hosp, Guangdong Lung Canc Inst, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China

[2] Guangdong Acad Med Sci, 106 Zhongshan Er Rd, Guangzhou 510080, Guangdong, Peoples R China

[3] Southern Med Univ, Guangzhou, Guangdong, Peoples R China

来源：

TUMOR BIOLOGY | 2016年 / 37卷 / 04期

关键词：

PD-L1; TILs; Checkpoint blockade; Immunotherapy; Immune resistance; Treatment strategy; T-CELL INFILTRATION; DEATH-LIGAND; PD-L1; EXPRESSION; IMMUNE ESCAPE; TUMOR MICROENVIRONMENT; ANTI-PD-L1; ANTIBODY; B7-H1; PLUS IPILIMUMAB; UP-REGULATION; CANCER;

D O I：

10.1007/s13277-016-4812-9

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Programmed cell death protein-1 (PD-1) and ligand (PD-L1) provide an important escape mechanism from immune attack, and blockade therapy of these proteins show promising clinical benefits in many types of cancer. PD-L1 can be induced by interferon-gamma (IFN-gamma), hypoxia, or toll-like receptor (TLR)-mediated pathways that confer adaptive immune resistance, or upregulated by oncogenic signals leading to constitutive expression and resulting in intrinsic immune resistance. The PD-1/PD-L1 checkpoint blockade, which targets regulatory pathways in T cells to overcome immune resistance, is correlated to PD-L1 expression pattern and the presence of tumor-infiltrating lymphocytes (TILs). Meanwhile, immunogenic mutation loads show significant response to checkpoint blockade, which is probably due to PD-1/L1 status and TIL content. Finally, the clinical strategies to design effective checkpoint-targeting immunotherapies are based on the classification of inducible/constitutive expression of PD-L1 and the presence of TILs.

引用

页码：4251 / 4261

页数：11

共 92 条

[1]

Afreen Sehar, 2014, Hematol Oncol Stem Cell Ther, V7, P1, DOI 10.1016/j.hemonc.2013.09.005

[2] Activation of the PD-1 Pathway Contributes to Immune Escape in EGFR-Driven Lung Tumors [J].

Akbay, Esra A. ;

Koyama, Shohei ;

Carretero, Julian ;

Altabef, Abigail ;

Tchaicha, Jeremy H. ;

Christensen, Camilla L. ;

Mikse, Oliver R. ;

Cherniack, Andrew D. ;

Beauchamp, Ellen M. ;

Pugh, Trevor J. ;

Wilkerson, Matthew D. ;

Fecci, Peter E. ;

Butaney, Mohit ;

Reibel, Jacob B. ;

Soucheray, Margaret ;

Cohoon, Travis J. ;

Janne, Pasi A. ;

Meyerson, Matthew ;

Hayes, D. Neil ;

Shapiro, Geoffrey I. ;

Shimamura, Takeshi ;

Sholl, Lynette M. ;

Rodig, Scott J. ;

Freeman, Gordon J. ;

Hammerman, Peter S. ;

Dranoff, Glenn ;

Wong, Kwok-Kin .

CANCER DISCOVERY, 2013, 3 (12) :1355-1363

[3] Signatures of mutational processes in human cancer [J].

Alexandrov, Ludmil B. ;

Nik-Zainal, Serena ;

Wedge, David C. ;

Aparicio, Samuel A. J. R. ;

Behjati, Sam ;

Biankin, Andrew V. ;

Bignell, Graham R. ;

Bolli, Niccolo ;

Borg, Ake ;

Borresen-Dale, Anne-Lise ;

Boyault, Sandrine ;

Burkhardt, Birgit ;

Butler, Adam P. ;

Caldas, Carlos ;

Davies, Helen R. ;

Desmedt, Christine ;

Eils, Roland ;

Eyfjord, Jorunn Erla ;

Foekens, John A. ;

Greaves, Mel ;

Hosoda, Fumie ;

Hutter, Barbara ;

Ilicic, Tomislav ;

Imbeaud, Sandrine ;

Imielinsk, Marcin ;

Jaeger, Natalie ;

Jones, David T. W. ;

Jones, David ;

Knappskog, Stian ;

Kool, Marcel ;

Lakhani, Sunil R. ;

Lopez-Otin, Carlos ;

Martin, Sancha ;

Munshi, Nikhil C. ;

Nakamura, Hiromi ;

Northcott, Paul A. ;

Pajic, Marina ;

Papaemmanuil, Elli ;

Paradiso, Angelo ;

Pearson, John V. ;

Puente, Xose S. ;

Raine, Keiran ;

Ramakrishna, Manasa ;

Richardson, Andrea L. ;

Richter, Julia ;

Rosenstiel, Philip ;

Schlesner, Matthias ;

Schumacher, Ton N. ;

Span, Paul N. ;

Teague, Jon W. .

NATURE, 2013, 500 (7463) :415-+

[4] Chemotherapeutic Targeting of Cancer-Induced Immunosuppressive Cells [J].

Alizadeh, Darya ;

Larmonier, Nicolas .

CANCER RESEARCH, 2014, 74 (10) :2663-2668

[5] PD-1 Blockade with Nivolumab in Relapsed or Refractory Hodgkin's Lymphoma [J].

Ansell, Stephen M. ;

Lesokhin, Alexander M. ;

Borrello, Ivan ;

Halwani, Ahmad ;

Scott, Emma C. ;

Gutierrez, Martin ;

Schuster, Stephen J. ;

Millenson, Michael M. ;

Cattry, Deepika ;

Freeman, Gordon J. ;

Rodig, Scott J. ;

Chapuy, Bjoern ;

Ligon, Azra H. ;

Zhu, Lili ;

Grosso, Joseph F. ;

Kim, Su Young ;

Timmerman, John M. ;

Shipp, Margaret A. ;

Armand, Philippe .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (04) :311-319

[6] Association of PD-L1 overexpression with activating EGFR mutations in surgically resected nonsmall- cell lung cancer [J].

Azuma, K. ;

Ota, K. ;

Kawahara, A. ;

Hattori, S. ;

Iwama, E. ;

Harada, T. ;

Matsumoto, K. ;

Takayama, K. ;

Takamori, S. ;

Kage, M. ;

Hoshino, T. ;

Nakanishi, Y. ;

Okamoto, I. .

ANNALS OF ONCOLOGY, 2014, 25 (10) :1935-1940

[7] Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer [J].

Brahmer, Julie ;

Reckamp, Karen L. ;

Baas, Paul ;

Crino, Lucio ;

Eberhardt, Wilfried E. E. ;

Poddubskaya, Elena ;

Antonia, Scott ;

Pluzanski, Adam ;

Vokes, Everett E. ;

Holgado, Esther ;

Waterhouse, David ;

Ready, Neal ;

Gainor, Justin ;

Aren Frontera, Osvaldo ;

Havel, Libor ;

Steins, Martin ;

Garassino, Marina C. ;

Aerts, Joachim G. ;

Domine, Manuel ;

Paz-Ares, Luis ;

Reck, Martin ;

Baudelet, Christine ;

Harbison, Christopher T. ;

Lestini, Brian ;

Spigel, David R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (02) :123-135

[8] Safety and Activity of Anti-PD-L1 Antibody in Patients with Advanced Cancer [J].

Brahmer, Julie R. ;

Tykodi, Scott S. ;

Chow, Laura Q. M. ;

Hwu, Wen-Jen ;

Topalian, Suzanne L. ;

Hwu, Patrick ;

Drake, Charles G. ;

Camacho, Luis H. ;

Kauh, John ;

Odunsi, Kunle ;

Pitot, Henry C. ;

Hamid, Omid ;

Bhatia, Shailender ;

Martins, Renato ;

Eaton, Keith ;

Chen, Shuming ;

Salay, Theresa M. ;

Alaparthy, Suresh ;

Grosso, Joseph F. ;

Korman, Alan J. ;

Parker, Susan M. ;

Agrawal, Shruti ;

Goldberg, Stacie M. ;

Pardoll, Drew M. ;

Gupta, Ashok ;

Wigginton, Jon M. .

NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (26) :2455-2465

[9] Neo-antigens predicted by tumor genome meta-analysis correlate with increased patient survival [J].

Brown, Scott D. ;

Warren, Rene L. ;

Gibb, Ewan A. ;

Martin, Spencer D. ;

Spinelli, John J. ;

Nelson, Brad H. ;

Holt, Robert A. .

GENOME RESEARCH, 2014, 24 (05) :743-750

[10] Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers [J].

Carbognin, Luisa ;

Pilotto, Sara ;

Milella, Michele ;

Vaccaro, Vanja ;

Brunelli, Matteo ;

Calio, Anna ;

Cuppone, Federica ;

Sperduti, Isabella ;

Giannarelli, Diana ;

Chilosi, Marco ;

Bronte, Vincenzo ;

Scarpa, Aldo ;

Bria, Emilio ;

Tortora, Giampaolo .

PLOS ONE, 2015, 10 (06)

← 1 2 3 4 5 6 7 8 9 10 →